Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

t care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about EUR183 million, close to 19% of consolidated sales, which amounted to EUR971 million while total revenues exceeded EUR1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Reglement Differe" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at http://www.ipsen.com.

Ipsen Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, currentt views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Notably, future currency fluctuations may negatively impact the profitability of the Group and its ability to reach its objectives. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CT (PRWEB) July 30, 2014 Connecticut ... development organization based in East Hartford, Conn., was awarded ... Phase II of a project that will determine the ... in rural north-central Connecticut. USDA Rural Development provided $53,000 ... program for the second phase of the feasibility study ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... The advanced optical methods and applications ... driving a revolution in the neurosciences were the inspiration ... by SPIE, the international society for optics and ... launch of the BRAIN Initiative in the United States, ... a vision for and provide examples of the impact ...
(Date:7/29/2014)... HOUSTON (July 29, 2014) Tough, ultralight foam ... and shape through a chemical process invented at Rice ... "GO-0.5BN" looks like a nanoscale building, with floors and ... a pair of two-dimensional materials: floors and walls of ... boron nitride platelets. , The researchers say the ...
Breaking Biology Technology:USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Tough foam from tiny sheets 2
... Solution ... U.S. Critical Care Crisis, BALTIMORE, May 20, 2008 ICU ... at hospitals using,the eICU(R) care delivery model, according to results released ... Multimedia News Release, go to:, http://www.prnewswire.com/mnr/visicu/33159/ , Data from more ...
... AMES, Iowa, May 20 Advanced Analytical Technologies,Inc. ... newest instrument platform,the DNA PROfiler(TM) system, at BIO ... the time to identify infections which could help,clinicians ... Dr. Steven J Lasky, CEO of AATI, states, ...
... Turtle Island Soup has launched a,new ... ingredients shown to have,important health benefits, including ... The new Souper Food soups are powered ... http://www.ganedenlabs.com/ourScience.html ), a probiotic that has been,shown ...
Cached Biology Technology:Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality: 2Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality: 3Video: Data From 185,000 ICU Admissions Show Significant Reductions in Mortality: 4Advanced Analytical Unveils New Instrument for Rapid Microbial Identification at BIO 2008 2Turtle Island Soup Gets 'Souped Up' with New Probiotic, GandenBC30 2Turtle Island Soup Gets 'Souped Up' with New Probiotic, GandenBC30 3
(Date:7/28/2014)... Food and Drug Administration (FDA) for other purposes can ... human cells, including those that cause Legionnaires, disease, brucellosis, ... mBio , the online open-access journal of the American ... non-antibiotic drugs that could one day help curb bacterial ... list inhibit the growth of at least three of ...
(Date:7/28/2014)... United States have a circulatory problem of the legs ... may even require surgery in serious cases. This disease ... turn, limb amputation. , At The University of Texas ... tested a non-surgical preventative treatment in a mouse model ... blood circulation. Their proof-of-concept study appears in the ...
(Date:7/28/2014)... that the effects of a commonly used anesthetic drug ... The study, published in this week,s issue of the ... at the University of California, San Diego and Weill ... concerns, arising from multiple studies on humans over the ... increase their susceptibility to long-term cognitive and behavioral deficits, ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... the lineage of primates, according to scientific gospel, social ... as food, territory and reproduction. , That may well ... groundbreaking study researchers from the University of Wisconsin-Madison have ... from basic motivations to be with one another. What's ...
... damaged by ultraviolet (UV) light. , Ohio State University ... to watch strands of DNA in the laboratory sustain damage ... common chemical reaction among a family of reactions on the ... this key reaction happens with astounding speed -- in less ...
... are creating a technology that will allow doctors and ... humans and animals and watch their bones move in ... , This high-resolution, high-speed imaging system will contribute ... injuries and help scientists understand the evolution of complex ...
Cached Biology News:In young mice, gregariousness seems to reside in the genes 2In young mice, gregariousness seems to reside in the genes 3Scientists see DNA get 'sunburned' for the first time 2Scientists see DNA get 'sunburned' for the first time 3Bones in motion: Brown scientists to create new 3-D X-ray system 2Bones in motion: Brown scientists to create new 3-D X-ray system 3
Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
Peptide-affinity Purified Polyclonal Antibody to MTR...
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Polyclonal Antibody to PRG3...
Biology Products: